Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | NCF1 | P14598 | 1/20 | 0.53 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.43 |
| ▸ | LSS | P48449 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334686 | 0.86 | MAPT (0.54) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL7329597 | 0.83 | CHKA (0.47) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL5760023 | 0.81 | CHKA (0.53) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL5803729 | 0.81 | CHKA (0.53) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL4713972 | 0.81 | CHKA (0.53) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL4717561 | 0.81 | CHKA (0.53) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL785122 | 0.81 | CHKA (0.53) | CHKAADRB2NCF1PLD1KDM1A | |
| SCHEMBL26627856 | 0.81 | CHKA (0.53) | CHKAADRB2NCF1PLD1ITGB3 | |
| SCHEMBL987932 | 0.81 | MBTD1 (0.52) | HRH3 | |
| Ammonia Solution, Strong SCHEMBL5844271 | 0.80 | CHKA (0.52) | CHKAADRB2NCF1PLD1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741386-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2025-09-18 | — | — | US | disclosed |
| EP-4516779-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025007777-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-118660872-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023208130-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116496252-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220289727-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-09-15 | — | — | US | disclosed |
| EP-4017850-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114258392-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| US-5556977-A | ANTIAGGLOMERANTS FOR CELLS, ANTICOAGULANTS, ANTIISCHEMIC AGENTS USING PYRIDINYLPIPERAZINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-09-17 | — | — | US | disclosed |
| CN-1120334-A | Heterocyclic derivatives as platelet aggregation inhibitors | ZENECA LTD (GB) | 1996-04-10 | — | — | CN | disclosed |
| EP-0691959-A1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-17 | — | — | EP | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022834-A1 | HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| US-5057528-A | AMINO-PYRIDINE COMPOUNDS USEFUL AS ANTI-ARRHYTHMIC AGENTS | PFIZER INC. (US) | 1991-10-15 | — | — | US | disclosed |
| US-4968704-A | PROLONG DURATION OF ACTION POTENTIAL IN CARDIAC MUSCLE AND CONDUCTING TISSUE | PFIZER INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0359389-A1 | Antiarrhythmic agents | Pfizer Limited (GB) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289727-A1 | ENZYME INHIBITORS | SERPINB1, ACE, GAA | CHKA 2511/4885ADRB2 1754/4885NCF1 1538/4885 |
| US-20250289799-A1 | PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | USP1, UPP1, UFL1 | CHKA 3675/4885ADRB2 4175/4885NCF1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.